ConjuChem Inc

CJB-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about CJB-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
November 26, 2007
Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
November 26, 2007
Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months.
DON'T BUY
DON'T BUY
April 7, 2005
Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
April 7, 2005
Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.
WEAK BUY
WEAK BUY
February 7, 2005
Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
February 7, 2005
Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team.
WAIT
WAIT
January 6, 2005
Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
January 6, 2005
Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem.
DON'T BUY
DON'T BUY
November 4, 2004
The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
November 4, 2004
The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market.
WAIT
WAIT
September 24, 2004
Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
September 24, 2004
Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time.
DON'T BUY
DON'T BUY
September 8, 2004
The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
September 8, 2004
The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term.
WEAK BUY
WEAK BUY
August 23, 2004
Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
August 23, 2004
Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.
DON'T BUY
DON'T BUY
August 6, 2004
Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
August 6, 2004
Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising.
TOP PICK
TOP PICK
July 30, 2004
Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
July 30, 2004
Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.
DON'T BUY
DON'T BUY
July 28, 2004
Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
July 28, 2004
Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.
DON'T BUY
DON'T BUY
July 15, 2004
A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
July 15, 2004
A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.
BUY
BUY
July 8, 2004
An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.
Show full opinionHide full opinion
An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.
BUY
BUY
May 12, 2004
Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.
Show full opinionHide full opinion
Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.
DON'T BUY
DON'T BUY
April 22, 2004
Has had a huge move. Has moved too far, too fast. Solid programs. Expensive.
Show full opinionHide full opinion
ConjuChem Inc (CJB-T)
April 22, 2004
Has had a huge move. Has moved too far, too fast. Solid programs. Expensive.
Showing 1 to 15 of 23 entries

ConjuChem Inc(CJB-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for ConjuChem Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

ConjuChem Inc(CJB-T) Frequently Asked Questions

What is ConjuChem Inc stock symbol?

ConjuChem Inc is a OTC stock, trading under the symbol CJB-T on the (). It is usually referred to as or CJB-T

Is ConjuChem Inc a buy or a sell?

In the last year, there was no coverage of ConjuChem Inc published on Stockchase.

Is ConjuChem Inc a good investment or a top pick?

ConjuChem Inc was recommended as a Top Pick by Peter Hodson on 2007-11-26. Read the latest stock experts ratings for ConjuChem Inc.

Why is ConjuChem Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is ConjuChem Inc worth watching?

In the last year 0 stock analysts on Stockchase covered ConjuChem Inc. The stock is worth watching.

What is ConjuChem Inc stock price?

On , ConjuChem Inc (CJB-T) stock closed at a price of $.